 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, we and our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and TriclonicsTM, today announced the launch of a proposed underwritten public offering of up to 60 million of its common shares. All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 9 million of its common shares. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 